Sugi Predict

Sugi Predict / Compounds / SCHEMBL1077415

SCHEMBL1077415

SCHEMBL1077415

Cc1c(C#N)c2ccccc2n1-c1ccc(O)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ STAT3 P40763 1/20 0.50
▸ LMNA P02545 6/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ GLA P06280 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.46
▸ MAPT P10636 5/20 0.44
▸ KDM4E B2RXH2 4/20 0.44
▸ HTT P42858 4/20 0.44
▸ GAA P10253 3/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ NCOA3 Q9Y6Q9 1/20 0.44
▸ USP14 P54578 2/20 0.43
▸ GFER P55789 1/20 0.43
▸ EGFR P00533 1/20 0.42
▸ SRC P12931 1/20 0.42
▸ TSHR P16473 4/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27835949 0.87 ALDH1A1 (0.55) ALDH1A1MAPK1STAT3LMNAL3MBTL1
SCHEMBL1076313 0.83 KDM4E (0.46) ALDH1A1MAPK1STAT3LMNAL3MBTL1
SCHEMBL12670811 0.83 RORC (0.57) ALDH1A1MAPK1STAT3LMNAL3MBTL1
SCHEMBL4066957 0.82 HTT (0.56) ALDH1A1MAPK1STAT3LMNAL3MBTL1
SCHEMBL1075730 0.82 L3MBTL1 (0.44) ALDH1A1MAPK1STAT3LMNAL3MBTL1
SCHEMBL1075868 0.81 KDM4E (0.42) ALDH1A1MAPK1STAT3LMNAL3MBTL1
SCHEMBL1076256 0.81 ALDH1A1 (0.42) ALDH1A1MAPK1STAT3LMNAL3MBTL1
SCHEMBL1076907 0.80 ALDH1A1 (0.43) ALDH1A1MAPK1STAT3LMNAL3MBTL1
SCHEMBL1035637 0.80 ALDH1A1 (0.41) ALDH1A1MAPK1STAT3LMNAL3MBTL1
SCHEMBL1077453 0.80 ALDH1A1 (0.41) ALDH1A1MAPK1STAT3LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2276732-B1 NOVEL ESTROGEN RECEPTOR LIGANDS KAROBIO AB (SE) 2015-05-20 — — EP claimed
CN-102066323-B Novel estrogen receptor ligands KAROBIO AB 2015-05-13 — — CN claimed
US-8653072-B2 Estrogen receptor ligands KARO BIO AB (SE) 2014-02-18 — — US claimed
US-20130131061-A1 Novel Estrogen Receptor Ligands KARO BIO AB (SE) 2013-05-23 — — US claimed
US-8367665-B2 Estrogen receptor ligands KARO BIO AB (SE) 2013-02-05 — — US claimed
US-20110190294-A1 NOVEL ESTROGEN RECEPTOR LIGANDS OASMIA PHARMACEUTICAL AB (SE) 2011-08-04 — — US claimed
CN-102066323-A Novel estrogen receptor ligands KAROBIO AB 2011-05-18 — — CN claimed
EP-2276732-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-01-26 — — EP claimed
WO-2009127686-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2009-10-22 — — WO claimed
EP-3782616-B1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES UNIV CALIFORNIA (US) 2023-11-01 — — EP disclosed
US-11628146-B2 Estrogen receptor ligand treatment for neurodegenerative diseases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-04-18 — — US disclosed
EP-3782616-A1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES The Regents of The University of California (US) 2021-02-24 — — EP disclosed
US-20210008002-A1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-01-14 — — US disclosed
US-10758496-B2 Estrogen receptor ligand treatment for neurodegenerative diseases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-09-01 — — US disclosed
US-8653072-B2 Estrogen receptor ligands KARO BIO AB (SE) 2014-02-18 — — US disclosed
US-20130131061-A1 Novel Estrogen Receptor Ligands KARO BIO AB (SE) 2013-05-23 — — US disclosed
US-8367665-B2 Estrogen receptor ligands KARO BIO AB (SE) 2013-02-05 — — US disclosed
US-20110190294-A1 NOVEL ESTROGEN RECEPTOR LIGANDS OASMIA PHARMACEUTICAL AB (SE) 2011-08-04 — — US disclosed
EP-2276732-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-01-26 — — EP disclosed
WO-2009127686-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2009-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210008002-A1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES ESR2, ESRRG, ESR1 ALDH1A1 2803/4885MAPK1 2713/4885STAT3 2322/4885
US-11628146-B2 Estrogen receptor ligand treatment for neurodegenerative diseases ESR2, ESRRG, ESR1 ALDH1A1 2803/4885MAPK1 2713/4885STAT3 2322/4885
US-20130131061-A1 Novel Estrogen Receptor Ligands ESR1, GPER1, ESRRA ALDH1A1 1765/4885MAPK1 2293/4885STAT3 358/4885
US-20110190294-A1 NOVEL ESTROGEN RECEPTOR LIGANDS ESR1, GPER1, ESRRA ALDH1A1 1909/4885MAPK1 2359/4885STAT3 377/4885
US-10758496-B2 Estrogen receptor ligand treatment for neurodegenerative diseases ESR2, ESRRG, ESR1 ALDH1A1 2803/4885MAPK1 2713/4885STAT3 2322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.